Mycovia Pharmaceuticals Initiates Additional Phase 3 Clinical Study Evaluating VT-1161 for the Treatment of Vulvovaginal Candidiasis

Durham, N.C. – February 27, 2019 – Mycovia Pharmaceuticals, a company developing therapies in women’s health and dermatology, today announced the initiation of an additional Phase 3 clinical study called ultraVIOLET to evaluate the safety and efficacy of lead candidate, VT-1161, and its ability to treat acute infections in women with recurrent vulvovaginal candidiasis (RVVC) compared to fluconazole, the current standard of care.